MRK

$MRK

Merck & Co., Inc.

Global pharmaceutical leader known for Keytruda cancer immunotherapy and vaccines.

Healthcare
$144.07
-0.39 (-0.27%)
Day Range$142.31 - $144.89
Prev Close$144.46

MRK key facts as of November 14, 2026

Latest AI research report
MRK Stock Analysis: Pipeline and Valuation (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (5 Strong Buy, 14 Buy, 9 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$159.45 mean (range $105.00 to $180.00) (as of November 17, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
19 Buy / 9 Hold / 0 Sell
Price Target
$159.45
10.7% upside
Subscribers
1
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

NEUTRAL

MRK Stock Analysis: Pipeline and Valuation

Merck closed Friday, November 13, at $147.76 after a recent quarterly earnings beat and two positive EU committee opinions. Pipeline progress and a 2.3% dividend yield are balanced by negative earnings growth, meaningful debt and uncertainty around future growth as Keytruda approaches patent-related challenges.

Nov 14, 2026

MRK FAQ

What is StockAlpha's latest view on MRK?

StockAlpha's latest AI research report on Merck & Co., Inc. (MRK), "MRK Stock Analysis: Pipeline and Valuation", was published on November 14, 2026 and rates the overall sentiment as neutral. Merck closed Friday, November 13, at $147.76 after a recent quarterly earnings beat and two positive EU committee opinions. Pipeline progress and a 2.3% dividend yield are balanced by negative earnings growth, meaningful debt and uncertainty around future growth as Keytruda approaches patent-related challenges.

When was the MRK research last updated?

The most recent MRK report was published on November 14, 2026.

What do analysts expect for MRK?

As of November 1, 2026, the analyst consensus on MRK is Strong Buy (5 Strong Buy, 14 Buy, 9 Hold, 0 Sell, 0 Strong Sell). As of November 17, 2026, the analyst price target is $159.45 mean (range $105.00 to $180.00).

Is this MRK research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring